2-isobutyl-4,5-diphenyloxazole | 872806-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-isobutyl-4,5-diphenyloxazole
• 英文别名: 2-isobutyl-4,5-diphenyl-oxazole；2-Isobutyl-4,5-diphenyl-oxazol；2-(2-Methylpropyl)-4,5-diphenyl-1,3-oxazole
• CAS: 872806-27-4
• 化学式: C₁₉H₁₉NO
• 分子量: 277.366
• InChiKey: QYVFRPORWLGAJH-UHFFFAOYSA-N

物化性质

• 熔点：
  224 °C
• 沸点：
  381.7±11.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-isobutyl-4,5-diphenyloxazole 在 ammonium cerium(IV) nitrate 、 水 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以84%的产率得到N-(3-methylbutanoyl)benzamide
  参考文献：
  名称：

  硝酸铈铵可促进恶唑的氧化。

  摘要：

  硝酸铈铵促进了具有各种取代方式的4,5-二苯基恶唑和恶唑的氧化反应。该转化导致以良好的产率形成相应的酰亚胺，并容许恶唑部分上的多种官能团和取代基。[反应：请参见文字]。

  DOI：

  10.1021/ol0624530
• 作为产物：
  描述：

  异戊酸 在 乙酸铵 、 4-二甲氨基吡啶 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 2-isobutyl-4,5-diphenyloxazole
  参考文献：
  名称：

  硝酸铈铵可促进恶唑的氧化。

  摘要：

  硝酸铈铵促进了具有各种取代方式的4,5-二苯基恶唑和恶唑的氧化反应。该转化导致以良好的产率形成相应的酰亚胺，并容许恶唑部分上的多种官能团和取代基。[反应：请参见文字]。

  DOI：

  10.1021/ol0624530

文献信息

• Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted .alpha. to the oxazole ring
  作者：Nicholas A. Meanwell、Michael J. Rosenfeld、J. J. Kim Wright、Catherine L. Brassard、John O. Buchanan、Marianne E. Federici、J. Stuart Fleming、Marianne Gamberdella、Karen S. Hartl

  DOI：10.1021/jm00076a017

  日期：1993.11

  inhibited platelet aggregation with an IC50 of 0.08 microM, 15-fold more potent than the unsubstituted prototype 2. The potency of 12a was found to be sensitive to variation of the methoxy moiety. The ethyl (12b) and isopropyl (12d) esters were less effective as were the acid 12e and a series of amides (12f-h). Other substituents introduced at this site of the pharmacophore included P(O)(OEt)2 (25), SCH3

  4,5-二苯基恶唑衍生物2-4先前被确定为非前列腺素前列环素（PGI2）模拟物。合成了一系列在恶唑环的碳原子α处带有2-4个取代基的衍生物，并将其作为体外ADP诱导的人血小板聚集的抑制剂。在不饱和系列中，以几何异构体的均等混合物形式评估的α-甲乙氧基衍生物10a抑制了血小板凝集，IC50为0.36 microM。对各个甲酯衍生物（E）-9a和（Z）-9a的评估表明，（E）-9a的效力比（Z）-9a高10倍。在饱和系列中，α-甲氧基甲氧基取代的化合物12a抑制血小板凝集，IC50为0.08 microM，效力比未取代的原型2高15倍。发现12a的效力对甲氧基部分的变化敏感。乙基（12b）和异丙基（12d）酯的效果不如酸12e和一系列酰胺（12f-h）。在药效团此位点引入的其他取代基包括P（O）（OEt）2（25），SCH3（31a），S（O）CH3（31b），SO2CH3（31c），异丙基（
• COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS
  申请人：GARVEY David S.

  公开号：US20080275010A1

  公开（公告）日：2008-11-06

  Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.

  本发明涉及已被替换为氮单氧化物基团的非甾体抗炎药；包括（i）非甾体抗炎药，可选择性地被替换为氮单氧化物基团和（ii）直接捐赠、转移或释放氮单氧化物基团的化合物（优选为带电物种，特别是亚硝酸盐）的组合物；以及使用这些组合物治疗炎症、疼痛、胃肠道损伤和/或发热的方法。这些化合物和组合物可以保护免受非甾体抗炎药引起的胃肠道、肾脏和其他毒性的影响。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093671A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝酰化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性内皮源性松弛因子的水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID，可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
  申请人：Earl Richard

  公开号：US20110098253A1

  公开（公告）日：2011-04-28

  The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

  该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法，该组合物包括至少一种硝化的非甾体类抗炎药，以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。
• Synthesis of 2,4,5-trisubstituted oxazoles from 1,2-diketones and amines by using an electrochemical method
  作者：Liangxiao Wei、Gaoqing Yuan

  DOI：10.1016/j.tet.2023.133246

  日期：2023.2

  An efficient electrochemical synthesis of trisubstituted oxazoles from readily available 1,2-diketones and amines is described. With KI as the electrocatalyst, t-BuOK as the base and MeOH as the electrolytic solvent, the electrochemical synthesis could be smoothly performed in an undivided cell to afford 2,4,5-trisubstituted oxazoles in good yields at room temperature.

  描述了从容易获得的 1,2-二酮和胺中高效电化学合成三取代恶唑。以 KI 为电催化剂，t -BuOK 为碱，MeOH 为电解溶剂，电化学合成可以在未分隔的电池中顺利进行，在室温下以良好的产率得到 2,4,5-三取代恶唑。